市場調査レポート

商品コード

1298405

アテローム性動脈硬化症治療市場：薬剤タイプ別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Atherosclerosis Drugs Market By Drug Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年04月01日 | 発行: Allied Market Research

| ページ情報: 英文 250 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 560,989円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 900,412円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,508,544円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

アテローム性動脈硬化症治療市場は、2022年に206億851万米ドルと評価され、2023年から2032年にかけて3％のCAGRを示し、2032年までに277億1,192万米ドルに達すると推定されています。

アテローム性動脈硬化症は、プラークの蓄積によって静脈が狭くなり、動脈壁が硬化する疾患です。血管に蓄積したプラークによって血流が妨げられ、血圧が上昇します。この状態では血流中に血栓が形成されるのが一般的で、さらに心臓発作、冠動脈疾患、末梢動脈疾患を引き起こす可能性があります。

動脈硬化治療薬は、コレステロール値を下げ、炎症を抑え、血栓を予防し、血流を改善することで、プラークの形成や体への影響を抑えることを目的としています。一般的に使用される動脈硬化治療薬には、血栓を予防するアスピリンなどの抗血小板薬、血圧を下げるアンジオテンシン変換酵素（ACE）阻害薬、血圧の維持とともに心臓発作のリスクを最小限に抑えるβ遮断薬などがあります。

世界のアテローム性動脈硬化症治療市場の成長は、心血管障害の憂慮すべき増加によって大きく左右されます。さらに、アテローム性動脈硬化症の早期診断と治療に対する意識の高まりがアテローム性動脈硬化症治療の需要を押し上げ、市場の成長にプラスの影響を与えています。しかし、アテローム性動脈硬化症治療の研究開発に関連するコストの急増は、市場の成長を阻害すると予想されます。これとは対照的に、公共部門だけでなく民間部門でも新薬治療への投資が急増しており、予測期間中のアテローム性動脈硬化症治療市場の成長に有利な機会を提供すると予想されています。

さらに、先進国と発展途上国の両方におけるヘルスケア支出の増加は、医療提供者が最新かつ最も効果的な治療を患者に提供しようとするため、動脈硬化治療薬の需要を促進します。

世界のアテローム性動脈硬化症治療市場は、薬剤タイプ、投与経路、流通チャネル、地域に区分されます。薬剤タイプ別では、抗血小板・抗凝固薬、コレステロール低下薬、ACE阻害薬、その他に分類されます。投与経路では、経口剤と注射剤に二分されます。流通チャネル別では、病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局に分類されます。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資ポケット
ポーターのファイブフォース分析
- 供給企業の交渉力
- 買い手の交渉力
- 代替品の脅威
- 新規参入業者の脅威
- 競合の激しさ
市場力学
- 促進要因
  - 国民の肥満の急増
  - 健康的なライフスタイルを促進するための政府イニシアチブの増加
  - 動脈硬化の新しい治療法の開発
- 阻害要因
  - 動脈硬化治療薬の副作用
- 機会
  - 新興市場における成長機会
COVID-19市場への影響分析

第4章アテローム性動脈硬化症治療市場：薬剤タイプ別

概要
- 市場規模および予測
抗血小板薬と抗凝固薬
- 主要市場動向、成長要因、機会
- 市場規模および予測：地域別
- 市場シェア分析：国別
コレステロール低下薬
- 主要市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
ACE阻害剤
- 主要市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第5章アテローム性動脈硬化症治療市場：投与経路別

概要
- 市場規模および予測
経口
- 主要市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
注射剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第6章アテローム性動脈硬化症治療市場：流通チャネル別

概要
- 市場規模と予測
病院薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
オンラインプロバイダー
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
ドラッグストアと小売薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第7章アテローム性動脈硬化症治療市場：地域別

概要
- 市場規模・予測：地域別
北米
- 主要動向と機会
- 市場規模・予測：薬剤タイプ別
- 市場規模・予測：投与経路別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - 米国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - カナダ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - メキシコ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬物タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
欧州
- 主要動向と機会
- 市場規模・予測：薬物タイプ別
- 市場規模・予測：投与経路別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - ドイツ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - フランス
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - 英国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - イタリア
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - スペイン
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - その他欧州
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
アジア太平洋地域
- 主要動向と機会
- 市場規模・予測：薬物タイプ別
- 市場規模・予測：投与経路別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - 日本
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - 中国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - オーストラリア
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - インド
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - 韓国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - その他アジア太平洋地域
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
ラテンアメリカ・中東・アフリカ
- 主要動向と機会
- 市場規模・予測：薬剤タイプ別
- 市場規模・予測：投与経路別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - ブラジル
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - サウジアラビア
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - 南アフリカ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬物タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別
  - その他の地域
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤タイプ別
  - 市場規模・予測：投与経路別
  - 市場規模・予測：流通チャネル別

第8章競合情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
トップ企業のポジショニング、2022年

第9章企業プロファイル

Amgen Inc.
Pfizer Inc.
AstraZeneca
Bayer AG
Sanofi
Novartis AG
Viatris Inc.
Bausch Health Companies Inc.
Lupin
Johnson & Johnson

図表

LIST OF TABLES

TABLE 01. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. ATHEROSCLEROSIS DRUGS MARKET FOR ANTI-PLATELET AND ANTICOAGULANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. ATHEROSCLEROSIS DRUGS MARKET FOR CHOLESTEROL LOWERING MEDICATION, BY REGION, 2022-2032 ($MILLION)
TABLE 04. ATHEROSCLEROSIS DRUGS MARKET FOR ACE INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. ATHEROSCLEROSIS DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 07. ATHEROSCLEROSIS DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 08. ATHEROSCLEROSIS DRUGS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 10. ATHEROSCLEROSIS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. ATHEROSCLEROSIS DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ATHEROSCLEROSIS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. ATHEROSCLEROSIS DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 20. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 23. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 26. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 29. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 32. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 33. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 35. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 36. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. UK ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. UK ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 39. UK ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 41. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 42. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 44. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 45. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 54. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 55. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 57. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 58. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 62. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 63. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 64. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 71. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 72. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 73. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 75. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 76. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 77. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 87. AMGEN INC.: KEY EXECUTIVES
TABLE 88. AMGEN INC.: COMPANY SNAPSHOT
TABLE 89. AMGEN INC.: PRODUCT SEGMENTS
TABLE 90. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 91. AMGEN INC.: KEY STRATERGIES
TABLE 92. PFIZER INC.: KEY EXECUTIVES
TABLE 93. PFIZER INC.: COMPANY SNAPSHOT
TABLE 94. PFIZER INC.: PRODUCT SEGMENTS
TABLE 95. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 96. ASTRAZENECA: KEY EXECUTIVES
TABLE 97. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 98. ASTRAZENECA: PRODUCT SEGMENTS
TABLE 99. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 100. ASTRAZENECA: KEY STRATERGIES
TABLE 101. BAYER AG: KEY EXECUTIVES
TABLE 102. BAYER AG: COMPANY SNAPSHOT
TABLE 103. BAYER AG: PRODUCT SEGMENTS
TABLE 104. BAYER AG: PRODUCT PORTFOLIO
TABLE 105. BAYER AG: KEY STRATERGIES
TABLE 106. SANOFI: KEY EXECUTIVES
TABLE 107. SANOFI: COMPANY SNAPSHOT
TABLE 108. SANOFI: PRODUCT SEGMENTS
TABLE 109. SANOFI: PRODUCT PORTFOLIO
TABLE 110. SANOFI: KEY STRATERGIES
TABLE 111. NOVARTIS AG: KEY EXECUTIVES
TABLE 112. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 113. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 114. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 115. NOVARTIS AG: KEY STRATERGIES
TABLE 116. VIATRIS INC.: KEY EXECUTIVES
TABLE 117. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 118. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 119. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 120. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
TABLE 121. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 122. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
TABLE 123. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 124. LUPIN: KEY EXECUTIVES
TABLE 125. LUPIN: COMPANY SNAPSHOT
TABLE 126. LUPIN: PRODUCT SEGMENTS
TABLE 127. LUPIN: PRODUCT PORTFOLIO
TABLE 128. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 129. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 130. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 131. JOHNSON & JOHNSON: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. ATHEROSCLEROSIS DRUGS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF ATHEROSCLEROSIS DRUGS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN ATHEROSCLEROSIS DRUGS MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALATHEROSCLEROSIS DRUGS MARKET
FIGURE 10. ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ANTI-PLATELET AND ANTICOAGULANTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR CHOLESTEROL LOWERING MEDICATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ACE INHIBITORS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR INJECTABLE, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. ATHEROSCLEROSIS DRUGS MARKET BY REGION, 2022
FIGURE 23. U.S. ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 24. CANADA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 25. MEXICO ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 26. GERMANY ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 27. FRANCE ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 28. UK ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 29. ITALY ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 30. SPAIN ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 31. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 32. JAPAN ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 33. CHINA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 34. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 35. INDIA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 36. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 38. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 39. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 40. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 41. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 46. COMPETITIVE DASHBOARD
FIGURE 47. COMPETITIVE HEATMAP: ATHEROSCLEROSIS DRUGS MARKET
FIGURE 48. TOP PLAYER POSITIONING, 2022
FIGURE 49. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 50. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 51. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 52. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 53. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 54. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
FIGURE 55. ASTRAZENECA: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 57. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. SANOFI: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. SANOFI: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 61. SANOFI: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 62. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 63. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 64. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 65. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 66. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. BAUSCH HEALTH COMPANIES INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 68. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 69. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 70. LUPIN: NET SALES, 2019-2021 ($MILLION)
FIGURE 71. LUPIN: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 72. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 73. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 74. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A13185

The atherosclerosis drugs market valued for $20,608.51 million in 2022 and is estimated to reach $27,711.92 million by 2032, exhibiting a CAGR of 3% from 2023 to 2032.

Atherosclerosis is a disorder in which veins get narrowed due to build of plaque, thus stiffening the artery walls. Blood flow is obstructed by plaque that builds up in blood vessels, which raises blood pressure. Formation of blood clots in the bloodstream is common in this condition, which can further lead to heart attack, coronary artery diseases, or peripheral artery diseases.

Atherosclerosis drugs aim to reduce the formation of plaque or its effects on the body by reducing cholesterol levels, decreasing inflammation, preventing blood clots, and improving blood flow. Commonly used atherosclerosis drugs include antiplatelet drugs such as aspirin, which prevent blood clots; angiotensin-converting enzyme (ACE) inhibitors, which reduce blood pressure; and beta-blockers, which minimize the risk of heart attack along with maintaining the blood pressure.

The growth of the global atherosclerosis drugs market is majorly driven by alarming increase in cardiovascular disorders. In addition, rise in awareness of early diagnosis and treatment of atherosclerosis boosts the demand for atherosclerosis drugs, which positively impacts the growth of the market. However, surge in cost associated with R&D of atherosclerosis drugs is expected to impede the market growth. In contrast, surge in investments for novel drug therapeutics in public as well as private sectors is anticipated to provide lucrative opportunities for the growth of the atherosclerosis drugs market during the forecast period.

Furthermore, rise in healthcare expenditure in both developed and developing countries drives demand for atherosclerosis drugs, as healthcare providers seek to offer the latest and most effective treatments to their patients.

The global atherosclerosis drugs market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is categorized into anti-platelet & anticoagulants, cholesterol lowering medication, ACE inhibitors, and others. Depending on route of administration, it is bifurcated into oral and injectable. By distribution channel, it is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global atherosclerosis drugs market. The key companies profiled in the report include Amgen Inc., Pfizer Inc., AstraZeneca, Bayer AG, Sanofi, Novartis AG, Viatris, Johnson & Johnson, Lupin, and Bausch Health Companies Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the atherosclerosis drugs market analysis from 2022 to 2032 to identify the prevailing atherosclerosis drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the atherosclerosis drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global atherosclerosis drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

Anti-platelet and Anticoagulants
Cholesterol Lowering Medication
ACE Inhibitors
Others

By Route of Administration

Oral
Injectable

By Distribution Channel

Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Amgen Inc.
AstraZeneca
Bausch Health Companies Inc.
Bayer AG
Johnson & Johnson
Lupin
Novartis AG
Pfizer Inc.
Sanofi
Viatris Inc.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Surge in obesity in populace
  - 3.4.1.2. Increase in government initiatives to promote healthy lifestyle
  - 3.4.1.3. Development of new treatments for atherosclerosis

3.4.2. Restraints
- 3.4.2.1. Side effects of atherosclerosis drugs

3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in the emerging markets

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Anti-platelet and Anticoagulants
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Cholesterol Lowering Medication
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. ACE Inhibitors
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country

CHAPTER 5: ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Oral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Injectable
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Online Providers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: ATHEROSCLEROSIS DRUGS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drug Type
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Drug Type
  - 7.2.5.1.3. Market size and forecast, by Route of Administration
  - 7.2.5.1.4. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Drug Type
  - 7.2.5.2.3. Market size and forecast, by Route of Administration
  - 7.2.5.2.4. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Drug Type
  - 7.2.5.3.3. Market size and forecast, by Route of Administration
  - 7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drug Type
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Drug Type
  - 7.3.5.1.3. Market size and forecast, by Route of Administration
  - 7.3.5.1.4. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Drug Type
  - 7.3.5.2.3. Market size and forecast, by Route of Administration
  - 7.3.5.2.4. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Drug Type
  - 7.3.5.3.3. Market size and forecast, by Route of Administration
  - 7.3.5.3.4. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Drug Type
  - 7.3.5.4.3. Market size and forecast, by Route of Administration
  - 7.3.5.4.4. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Drug Type
  - 7.3.5.5.3. Market size and forecast, by Route of Administration
  - 7.3.5.5.4. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Drug Type
  - 7.3.5.6.3. Market size and forecast, by Route of Administration
  - 7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drug Type
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Drug Type
  - 7.4.5.1.3. Market size and forecast, by Route of Administration
  - 7.4.5.1.4. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Drug Type
  - 7.4.5.2.3. Market size and forecast, by Route of Administration
  - 7.4.5.2.4. Market size and forecast, by Distribution Channel
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Drug Type
  - 7.4.5.3.3. Market size and forecast, by Route of Administration
  - 7.4.5.3.4. Market size and forecast, by Distribution Channel
  - 7.4.5.4. India
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Drug Type
  - 7.4.5.4.3. Market size and forecast, by Route of Administration
  - 7.4.5.4.4. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Drug Type
  - 7.4.5.5.3. Market size and forecast, by Route of Administration
  - 7.4.5.5.4. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Drug Type
  - 7.4.5.6.3. Market size and forecast, by Route of Administration
  - 7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drug Type
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Drug Type
  - 7.5.5.1.3. Market size and forecast, by Route of Administration
  - 7.5.5.1.4. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Drug Type
  - 7.5.5.2.3. Market size and forecast, by Route of Administration
  - 7.5.5.2.4. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Drug Type
  - 7.5.5.3.3. Market size and forecast, by Route of Administration
  - 7.5.5.3.4. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Drug Type
  - 7.5.5.4.3. Market size and forecast, by Route of Administration
  - 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Amgen Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Pfizer Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. AstraZeneca
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Bayer AG
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Sanofi
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Novartis AG
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Viatris Inc.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Bausch Health Companies Inc.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Lupin
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Johnson & Johnson
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance

アテローム性動脈硬化症治療市場：薬剤タイプ別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Atherosclerosis Drugs Market By Drug Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章アテローム性動脈硬化症治療市場：薬剤タイプ別

第5章アテローム性動脈硬化症治療市場：投与経路別

第6章アテローム性動脈硬化症治療市場：流通チャネル別

第7章アテローム性動脈硬化症治療市場：地域別

第8章競合情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Drug Type

By Route of Administration

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE

CHAPTER 5: ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 6: ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: ATHEROSCLEROSIS DRUGS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

アテローム性動脈硬化症治療市場：薬剤タイプ別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Atherosclerosis Drugs Market By Drug Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 アテローム性動脈硬化症治療市場：薬剤タイプ別

第5章 アテローム性動脈硬化症治療市場：投与経路別

第6章 アテローム性動脈硬化症治療市場：流通チャネル別

第7章 アテローム性動脈硬化症治療市場：地域別

第8章 競合情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Drug Type

By Route of Administration

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE

CHAPTER 5: ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 6: ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: ATHEROSCLEROSIS DRUGS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章アテローム性動脈硬化症治療市場：薬剤タイプ別

第5章アテローム性動脈硬化症治療市場：投与経路別

第6章アテローム性動脈硬化症治療市場：流通チャネル別

第7章アテローム性動脈硬化症治療市場：地域別

第8章競合情勢

第9章企業プロファイル